Gastroenteropancreatic Neuroendocrine Tumors Enrolling by Invitation Phase 1 / 2 Trials for Irinotecan (DB00762)

Also known as: Gastro-entero-pancreatic Neuroendocrine Tumor / Gastro-entero Pancreatic Neuroendocrine Tumors / Gastro Entero Pancreatic Neuroendocrine Tumors / Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) / Neuroendocrine Gastroenteropancreatic Tumour / Gastro-entero-pancreatic Neuroendocrine Tumors / GEP-NET / Gastro-enteropancreatic Neuroendocrine Tumor / Gastro-Entero-Pancreatic Tumors (GEPs) / Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) / Neuroendocrine Tumors,Gastroenteropancreatic / Gastroenteral-Pancreatic Neuroendocrine Tumors / Gastroenteropancreatic Neuroendocrine Tumours / Gastroenteropancreatic Neuroendocrine Tumor / Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) / Gastroenteropancreatic Neuroendocrine Tumor Disease / Gep Net / Gastroenteropancreatic neuroendocrine tumour disease

IndicationStatusPhase
DBCOND0063370 (Gastroenteropancreatic Neuroendocrine Tumors)Enrolling by Invitation1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05385861
Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NETTreatment